KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.

导出 LinkOut

翻译打印收藏纠错

第一作者： Yanmin,Xu

第一单位： Pathology Center and Department of Pathology, Soochow University, Suzhou, China.

作者： Yanmin,Xu ^[1] ; Huailong,Xu ^[2] ; Mingyuan,Li ^[3] ; Hua,Wu ^[1] ; Yanhe,Guo ^[3] ; Jun,Chen ^[2] ; Juanjuan,Shan ^[3] ; Xuejiao,Chen ^[3] ; Junjie,Shen ^[3] ; Qinghua,Ma ^[3] ; Jingxia,Liu ^[3] ; Meiling,Wang ^[3] ; Wenxu,Zhao ^[2] ; Juan,Hong ^[3] ; Yanan,Qi ^[3] ; Chao,Yao ^[2] ; Qianzhen,Zhang ^[3] ; Zhi,Yang ^[3] ; Cheng,Qian ^[4] ; Jianming,Li ^[5]

作者单位： Pathology Center and Department of Pathology, Soochow University, Suzhou, China. ^[1] Chongqing Institute of Precision Medicine and Biotechnology Co., Ltd., Chongqing, China. ^[2] Center of Biological Therapy, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China. ^[3] Center of Biological Therapy, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China. Electronic address: cqian8634@gmail.com. ^[4] Pathology Center and Department of Pathology, Soochow University, Suzhou, China. Electronic address: jianmingli@suda.edu.cn. ^[5]

关键词 EMT Hepatocellular carcinoma KIAA1199 Metastasis Sorafenib tolerance